Naeem Saira, Ogah Cyprian O, Mohammed Huda, Gabra Ingie M, Halawa Nouran, Malasevskaia Iana
Medicine, Faisalabad Medical University, Faisalabad, PAK.
Internal Medicine, Valley Baptist Hospital at University of Texas Rio Grande Valley, Harlingen, USA.
Cureus. 2024 Oct 31;16(10):e72771. doi: 10.7759/cureus.72771. eCollection 2024 Oct.
Type 2 diabetes mellitus (T2DM) is a major global health issue, affecting millions and leading to significant healthcare costs. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a potential treatment option. Still, their effects on body weight, body mass index (BMI), and body composition compared to other diabetes medications or placebos remain unclear. This systematic review investigates these effects in adults with T2DM. A comprehensive literature search was conducted from June 20, 2024, to July 5, 2024, across six databases and one register: PubMed, MEDLINE, Cochrane Library (CENTRAL), Europe PMC, ScienceDirect, ClinicalTrials.gov, and EBSCO Open Dissertation, yielding 2,425 records. Following the application of inclusion and exclusion criteria, 13 studies were selected for final analysis, encompassing a sample size of 37,619 participants, adhering to Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. The quality of the included studies was assessed using the Cochrane Risk-of-Bias Tool for randomized controlled trials and the Newcastle-Ottawa Scale for observational studies. Results indicate that SGLT2 inhibitors are significantly associated with reductions in body weight and BMI compared to other diabetes medications and placebo. These findings suggest that SGLT2 inhibitors improve glycemic control and facilitate effective weight management, underscoring their potential role in comprehensive diabetes care. Future research should focus on long-term outcomes and the integration of SGLT2 inhibitors into individualized treatment plans for patients with T2DM.
2型糖尿病（T2DM）是一个重大的全球健康问题，影响着数百万人，并导致了高昂的医疗费用。钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂已成为一种潜在的治疗选择。然而，与其他糖尿病药物或安慰剂相比，它们对体重、体重指数（BMI）和身体成分的影响仍不明确。本系统评价调查了这些药物对成年T2DM患者的影响。于2024年6月20日至2024年7月5日在六个数据库和一个登记处进行了全面的文献检索：PubMed、MEDLINE、Cochrane图书馆（CENTRAL）、欧洲生物医学中心、ScienceDirect、ClinicalTrials.gov和EBSCO开放学位论文库，共检索到2425条记录。在应用纳入和排除标准后，选择了13项研究进行最终分析，样本量为37619名参与者，遵循系统评价和Meta分析的首选报告项目（PRISMA）2020指南。使用Cochrane随机对照试验偏倚风险工具和纽卡斯尔-渥太华量表对纳入研究的质量进行评估。结果表明，与其他糖尿病药物和安慰剂相比，SGLT2抑制剂与体重和BMI的降低显著相关。这些发现表明，SGLT2抑制剂可改善血糖控制并促进有效的体重管理，突显了它们在糖尿病综合治疗中的潜在作用。未来的研究应聚焦于长期结果以及将SGLT2抑制剂纳入T2DM患者的个体化治疗方案。
